Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellectar BiosciencesCLRB -3.76%23 3-Year Share Buyback Ratio is -138.40 as of Mar. 2026. GuruFocus rates CLRB with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,196 Biotechnology companies, Cellectar Biosciences ranks worse than 93.31% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Cellectar Biosciences's current 3-Year Share Buyback Ratio was -138.40%.
The historical rank and industry rank for Cellectar Biosciences's 3-Year Share Buyback Ratio or its related term are showing as below:
CLRB'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -193.1 Med: -117.8 Max: -66
Current: -138.4
During the past 13 years, Cellectar Biosciences's highest 3-Year Share Buyback Ratio was -66.00%. The lowest was -193.10%. And the median was -117.80%.
CLRB's 3-Year Share Buyback Ratio is ranked worse than 93.31% of 1196
companies
in the Biotechnology industry
Industry Median: -11.75
vs CLRB: -138.40
Cellectar Biosciences (NAS:CLRB) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Cellectar Biosciences 3-Year Share Buyback Ratio Related Terms
CLRB vs DARE, NEUP, LGVN: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Cellectar Biosciences's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellectar Biosciences 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Cellectar Biosciences's 3-Year Share Buyback Ratio falls into.
Cellectar Biosciences 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -138.40 mean?
Cellectar Biosciences (CLRB) has a 3-Year Share Buyback Ratio of -138.40 as of Mar. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cellectar Biosciences and its competitors. According to the industry distribution chart, Cellectar Biosciences ranks #1116 out of 1196 companies in the Biotechnology industry, placing it in the top 93.3%.
Is Cellectar Biosciences' 3-Year Share Buyback Ratio too high?
Cellectar Biosciences' current 3-Year Share Buyback Ratio is -138.40. Based on the distribution chart, Cellectar Biosciences ranks #1116 out of 1196 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cellectar Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' 3-Year Share Buyback Ratio compare to DARE and NEUP?
According to the Biotechnology industry distribution chart, Cellectar Biosciences ranks #1116 out of 1196 companies for 3-Year Share Buyback Ratio. This places Cellectar Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Cellectar Biosciences and its competitors. Cellectar Biosciences's current 3-Year Share Buyback Ratio is -138.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current 3-Year Share Buyback Ratio of -138.40. The current 3-Year Share Buyback Ratio is -138.40. Cellectar Biosciences' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current 3-Year Share Buyback Ratio is -138.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
23GF Score
Get the complete analysis for CLRB
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLRB has been successfully added to your 
